MorphoSys (MOR) Given a €116.00 Price Target at Oddo Bhf

MorphoSys (ETR:MOR) has been given a €116.00 ($134.88) price objective by analysts at Oddo Bhf in a research report issued on Thursday. The brokerage presently has a “buy” rating on the stock. Oddo Bhf’s price target would suggest a potential upside of 9.23% from the company’s current price.

Several other research firms also recently commented on MOR. Independent Research set a €120.00 ($139.53) target price on MorphoSys and gave the company a “neutral” rating in a research report on Friday, July 20th. Deutsche Bank set a €120.00 ($139.53) target price on MorphoSys and gave the company a “neutral” rating in a research report on Monday, July 30th. Royal Bank of Canada set a €62.00 ($72.09) target price on MorphoSys and gave the company a “sell” rating in a research report on Thursday, July 19th. Commerzbank set a €98.00 ($113.95) target price on MorphoSys and gave the company a “buy” rating in a research report on Thursday, July 19th. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) target price on MorphoSys and gave the company a “buy” rating in a research report on Thursday, July 19th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of €96.40 ($112.09).

MorphoSys stock opened at €106.20 ($123.49) on Thursday. MorphoSys has a 12 month low of €49.63 ($57.71) and a 12 month high of €88.10 ($102.44).

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Further Reading: The risks of owning bonds

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply